GHTM

Global Health and Tropical Medicine

  • GHTM
    • About GHTM
    • Governance
    • Impact
    • Members
      • Population health, policies and services
        • PPS PhD members
        • PPS non PhD members
      • TB, HIV and opportunistic diseases and pathogens
        • THOP PhD members
        • THOP non PhD members
      • Vector-borne diseases
        • VBD PhD members
        • VBD non PhD members
      • Individual Health Care
        • IHC PhD members
        • IHC non PhD members
      • Tech & Admin support
    • Scientific Advisory Board
  • Research
    • Cross-cutting issues
      • Global Pathogen Dispersion and Population Mobility
      • Drug Discovery and Drug Resistance
      • Diagnostics
      • Public Health Information
      • Fair Research Partnerships
    • Research Groups
      • PPS – Population health, policies and services
      • THOP – TB, HIV and opportunistic diseases and pathogens
      • VBD – Vector borne diseases
      • IHC – Individual health care
    • Research in numbers
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
    • Projects
      • Ongoing Projects
      • Completed Projects
  • Outreach
    • Events
    • News
    • Policy Support & Community Outreach
  • Publications
    • 2024
    • 2023
    • 2022
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
  • Capacity Building
    • Education
      • Master Theses
      • PhD Theses
    • International
  • Infrastructures
  • Networks & Partnerships
  • Reports
    • GHTM
    • Scientific Advisory Board
    • FCT
Home / Archives for Infection Genetics and Evolution

Contribution of efflux activity to isoniazid resistance in the Mycobacterium tuberculosis complex.

  • Authors: Amaral L, Couto I, Machado D, Rodrigues L, Viveiros M
  • Journal: Infection Genetics and Evolution
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Contribution+of+efflux+activity+to+isoniazid+resistance+in+the+Mycobacterium+tuberculosis+complex.+Infection

Resistance to isoniazid (INH), one of the main drugs used in tuberculosis (TB) therapy, is mostly due to chromosomal mutations in target genes. However, approximately 20-30% of INH resistant Mycobacterium tuberculosis isolates do not have mutations in any of the genes associated with INH resistance.
Read More

Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: Performance evaluation of the new REGA version 3 and seven other tools

  • Authors: Abecasis AB, Camacho RJ, De Oliveira T, Deforche K, Faria NR, Gomez-Lopez A, Imbrechts S, Libin P, Pineda-Peña AC, Vandamme AM
  • Journal: Infection Genetics and Evolution
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/23660484

To investigate differences in pathogenesis, diagnosis and resistance pathways between HIV-1 subtypes, an accurate subtyping tool for large datasets is needed. We aimed to evaluate the performance of automated subtyping tools to classify the different subtypes and circulating recombinant forms using pol, the most sequenced region in clinical practice. We also present the upgraded version 3 of the Rega HIV subtyping tool (REGAv3).
Read More

Antiretroviral drug resistance in HIV-1 therapy-naive patients in Cuba

  • Authors: Abrahantes Y, Aleman Y, Alvarez A, Álvarez D, Aragonés C, Beheydt G, Campos J, Correa C, Dekeersmaeker N, Fonseca C, Imbrechts S, Kourí V, Martínez O, Perez J, Perez L, Schrooten Y, Soto Y, Van Laethem K, Vandamme AM, Vinken L
  • Publication Year: 2013
  • Journal: Infection Genetics and Evolution
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/23416260

In Cuba, antiretroviral therapy rollout started in 2001 and antiretroviral therapy coverage has reached almost 40% since then. The objectives of this study were therefore to analyze subtype distribution, and level and patterns of drug resistance in therapy-naive HIV-1 patients.
Read More

Population structure of Pneumocystis jirovecii isolated from immunodeficiency virus-positive patients

  • Authors: Antunes F, Esteves F, Gaspar J, Mansinho K, Matos O, Moser I, Tavares A
  • Journal: Infection Genetics and Evolution
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Population+structure+of+Pneumocystis+jirovecii+isolated+from+immunodeficiency+virus+positive+patients

Pneumocystis jirovecii pneumonia (PcP) is an important opportunistic infection among immunocompromised patients. Genetic characterization of P. jirovecii isolated from HIV-positive patients, based on identification of multiple nucleotide sequences at eight distinct loci, was achieved by using PCR with DNA sequencing and RFLP.
Read More

Comparative performance of the REGA subtyping tool version 2 versus version 1

  • Authors: Abecasis AB, Camacho RJ, De Oliveira T, Imbrechts S, Libin P, Vandamme AM, Wang Y
  • Journal: Infection Genetics and Evolution
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Comparative+performance+of+the+REGA+subtyping+tool+version+2+versus+version+1

The REGA HIV-1 subtyping tool is a phylogenetic-based method for subtyping HIV-1 genomic sequences that was published in 2005. The subtyping tool combines phylogenetic approaches with recombination detection methods.
Read More

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »

About GHTM

GHTM is a R&D Unit that brings together researchers with a track record in Tropical Medicine and International & Global Health. It aims at strengthening Portugal's role as a leading partner in the development and implementation of a global health research agenda. Our evidence-based interventions contribute to the promotion of equity in health and to improve the health of populations.

Contacts

Rua da Junqueira, 100
1349-008 Lisboa
Portugal

+351 213 652 600

  • E-mail
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Map

  • Events
  • Research Groups
  • Cross-cutting issues
© Copyright 2025 IHMT-UNL All Rights Reserved.
  • Universidade Nova de Lisboa
  • Fundação para a Ciência e a Tecnologia

    UIDB/04413/2020
    UIDP/04413/2020

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok